Which has preferable valuation & earnings, EWTX or SPTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Seaport Therapeutics N/A N/A -$74.88M -$12.12 N/A

Is EWTX or SPTX more profitable?

Seaport Therapeutics' return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Seaport Therapeutics N/A N/A N/A

Does the media favor EWTX or SPTX?

In the previous week, Edgewise Therapeutics had 2 more articles in the media than Seaport Therapeutics. MarketBeat recorded 8 mentions for Edgewise Therapeutics and 6 mentions for Seaport Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.01 beat Seaport Therapeutics' score of 0.36 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seaport Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, MANE or SPTX?

Veradermics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A -$70M -$1.90 N/A Seaport Therapeutics N/A N/A -$74.88M -$12.12 N/A

Is MANE or SPTX more profitable?

Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Seaport Therapeutics N/A N/A N/A

Does the media prefer MANE or SPTX?

In the previous week, Veradermics had 4 more articles in the media than Seaport Therapeutics. MarketBeat recorded 10 mentions for Veradermics and 6 mentions for Seaport Therapeutics. Seaport Therapeutics' average media sentiment score of 0.36 beat Veradermics' score of 0.28 indicating that Seaport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seaport Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SPTX or INDV?

In the previous week, Seaport Therapeutics had 4 more articles in the media than Indivior. MarketBeat recorded 6 mentions for Seaport Therapeutics and 2 mentions for Indivior. Indivior's average media sentiment score of 0.52 beat Seaport Therapeutics' score of 0.36 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seaport Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, SPTX or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Seaport Therapeutics N/A N/A -$74.88M -$12.12 N/A Structure Therapeutics N/A N/A -$141.20M -$1.00 N/A

Is SPTX or GPCR more profitable?

Seaport Therapeutics' return on equity of 0.00% beat Structure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Seaport Therapeutics N/A N/A N/A Structure Therapeutics N/A -25.56% -24.31%

Does the media prefer SPTX or GPCR?

In the previous week, Seaport Therapeutics had 4 more articles in the media than Structure Therapeutics. MarketBeat recorded 6 mentions for Seaport Therapeutics and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.73 beat Seaport Therapeutics' score of 0.36 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seaport Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Structure Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Seaport Therapeutics (SPTX) Competitors

$24.83 +0.75 (+3.11%)

As of 04:00 PM Eastern

Compare

SPTX vs. EWTX, MANE, INDV, GPCR, and CPRX

Should you buy Seaport Therapeutics stock or one of its competitors? Seaport Therapeutics's main competitors and comparable companies include Edgewise Therapeutics (EWTX), Veradermics (MANE), Indivior (INDV), Structure Therapeutics (GPCR), and Catalyst Pharmaceuticals (CPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Seaport Therapeutics compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Seaport Therapeutics (NASDAQ:SPTX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

In the previous week, Edgewise Therapeutics had 2 more articles in the media than Seaport Therapeutics. MarketBeat recorded 8 mentions for Edgewise Therapeutics and 6 mentions for Seaport Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.01 beat Seaport Therapeutics' score of 0.36 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seaport Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

Seaport Therapeutics' return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Seaport Therapeutics	N/A	N/A	N/A

Edgewise Therapeutics currently has a consensus price target of $50.33, indicating a potential upside of 13.85%. Seaport Therapeutics has a consensus price target of $38.40, indicating a potential upside of 54.65%. Given Seaport Therapeutics' higher probable upside, analysts clearly believe Seaport Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Summary

Edgewise Therapeutics beats Seaport Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Seaport Therapeutics compare to Veradermics?

Veradermics (NYSE:MANE) and Seaport Therapeutics (NASDAQ:SPTX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Veradermics had 4 more articles in the media than Seaport Therapeutics. MarketBeat recorded 10 mentions for Veradermics and 6 mentions for Seaport Therapeutics. Seaport Therapeutics' average media sentiment score of 0.36 beat Veradermics' score of 0.28 indicating that Seaport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seaport Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veradermics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

Veradermics presently has a consensus target price of $153.00, indicating a potential upside of 49.35%. Seaport Therapeutics has a consensus target price of $38.40, indicating a potential upside of 54.65%. Given Seaport Therapeutics' higher probable upside, analysts clearly believe Seaport Therapeutics is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Seaport Therapeutics	N/A	N/A	N/A

Summary

Veradermics beats Seaport Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Seaport Therapeutics compare to Indivior?

Seaport Therapeutics (NASDAQ:SPTX) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

60.3% of Indivior shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Indivior has a net margin of 26.65% compared to Seaport Therapeutics' net margin of 0.00%. Seaport Therapeutics' return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Indivior	26.65%	-283.11%	36.85%

Seaport Therapeutics currently has a consensus price target of $38.40, suggesting a potential upside of 54.65%. Indivior has a consensus price target of $45.17, suggesting a potential upside of 25.57%. Given Seaport Therapeutics' higher probable upside, equities research analysts plainly believe Seaport Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Seaport Therapeutics had 4 more articles in the media than Indivior. MarketBeat recorded 6 mentions for Seaport Therapeutics and 2 mentions for Indivior. Indivior's average media sentiment score of 0.52 beat Seaport Therapeutics' score of 0.36 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seaport Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A
Indivior	$1.33B	3.19	$210M	$2.79	12.89

Summary

Indivior beats Seaport Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Seaport Therapeutics compare to Structure Therapeutics?

Seaport Therapeutics (NASDAQ:SPTX) and Structure Therapeutics (NASDAQ:GPCR) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Seaport Therapeutics had 4 more articles in the media than Structure Therapeutics. MarketBeat recorded 6 mentions for Seaport Therapeutics and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.73 beat Seaport Therapeutics' score of 0.36 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seaport Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Structure Therapeutics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Seaport Therapeutics currently has a consensus target price of $38.40, indicating a potential upside of 54.65%. Structure Therapeutics has a consensus target price of $110.91, indicating a potential upside of 122.17%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Seaport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Seaport Therapeutics' return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Structure Therapeutics	N/A	-25.56%	-24.31%

91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Structure Therapeutics beats Seaport Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Seaport Therapeutics compare to Catalyst Pharmaceuticals?

Seaport Therapeutics (NASDAQ:SPTX) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Seaport Therapeutics currently has a consensus target price of $38.40, indicating a potential upside of 54.65%. Catalyst Pharmaceuticals has a consensus target price of $32.00, indicating a potential upside of 1.62%. Given Seaport Therapeutics' higher possible upside, research analysts plainly believe Seaport Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Seaport Therapeutics' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Seaport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Catalyst Pharmaceuticals has higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

In the previous week, Seaport Therapeutics had 6 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for Seaport Therapeutics and 0 mentions for Catalyst Pharmaceuticals. Seaport Therapeutics' average media sentiment score of 0.36 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Seaport Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Seaport Therapeutics	Neutral
Catalyst Pharmaceuticals	Neutral

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Catalyst Pharmaceuticals beats Seaport Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Seaport Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPTX vs. The Competition

Export

Metric	Seaport Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.33B	$12.55B	$7.31B	$12.77B
Dividend Yield	N/A	2.61%	2.54%	10.78%
P/E Ratio	-2.05	778.14	271.23	24.19
Price / Sales	N/A	961.13	696.77	129.00
Price / Cash	N/A	15.47	29.03	36.89
Price / Book	N/A	10.58	11.33	6.52
Net Income	-$74.88M	$2.80B	$3.46B	$347.63M
7 Day Performance	3.59%	3.95%	3.26%	1.60%
1 Month Performance	17.68%	6.54%	8.85%	5.27%
1 Year Performance	N/A	8.76%	27.68%	17.87%

Seaport Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPTX Seaport Therapeutics	2.9261 of 5 stars	$24.83 +3.1%	$38.40 +54.7%	N/A	$1.33B	N/A	N/A	N/A
EWTX Edgewise Therapeutics	3.026 of 5 stars	$44.17 +2.3%	$49.08 +11.1%	+201.1%	$4.80B	N/A	N/A	60
MANE Veradermics	2.2026 of 5 stars	$113.18 +2.0%	$153.00 +35.2%	N/A	$4.71B	N/A	N/A	19
INDV Indivior	3.8483 of 5 stars	$39.01 +2.1%	$45.17 +15.8%	+48.8%	$4.60B	$1.33B	13.98	1,051
GPCR Structure Therapeutics	2.4332 of 5 stars	$54.51 -0.3%	$110.91 +103.5%	+149.9%	$3.87B	N/A	N/A	136	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPTX) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seaport Therapeutics (SPTX) Competitors

SPTX vs. EWTX, MANE, INDV, GPCR, and CPRX

How does Seaport Therapeutics compare to Edgewise Therapeutics?

Summary

How does Seaport Therapeutics compare to Veradermics?

Summary

How does Seaport Therapeutics compare to Indivior?

Summary

How does Seaport Therapeutics compare to Structure Therapeutics?

Summary

How does Seaport Therapeutics compare to Catalyst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPTX vs. The Competition

Seaport Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seaport Therapeutics (SPTX) Competitors

SPTX vs. EWTX, MANE, INDV, GPCR, and CPRX

How does Seaport Therapeutics compare to Edgewise Therapeutics?

Does the media favor EWTX or SPTX?

Which has preferable valuation & earnings, EWTX or SPTX?

Is EWTX or SPTX more profitable?

Do analysts rate EWTX or SPTX?

Summary

How does Seaport Therapeutics compare to Veradermics?

Does the media prefer MANE or SPTX?

Which has higher earnings and valuation, MANE or SPTX?

Do analysts rate MANE or SPTX?

Is MANE or SPTX more profitable?

Summary

How does Seaport Therapeutics compare to Indivior?

Do insiders & institutionals believe in SPTX or INDV?

Is SPTX or INDV more profitable?

Do analysts recommend SPTX or INDV?

Does the media prefer SPTX or INDV?

Which has better earnings & valuation, SPTX or INDV?

Summary

How does Seaport Therapeutics compare to Structure Therapeutics?

Does the media prefer SPTX or GPCR?

Which has preferable earnings & valuation, SPTX or GPCR?

Do analysts rate SPTX or GPCR?

Is SPTX or GPCR more profitable?

Do insiders and institutionals believe in SPTX or GPCR?

Summary

How does Seaport Therapeutics compare to Catalyst Pharmaceuticals?

Do analysts rate SPTX or CPRX?

Is SPTX or CPRX more profitable?

Which has preferable valuation and earnings, SPTX or CPRX?

Does the media prefer SPTX or CPRX?

Do insiders & institutionals have more ownership in SPTX or CPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPTX vs. The Competition

Seaport Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools